Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

This study is testing a 3-drug combination — serplulimab (immunotherapy), lenvatinib (a targeted therapy), and paclitaxel (chemotherapy) — as a second-line treatment for people with advanced stomach or gastroesophageal junction cancer who previously received immunotherapy as their first treatment. **You may be eligible if...** - You are 18–75 years old - You have confirmed advanced gastric or gastroesophageal junction cancer - Your cancer either has a PD-L1 score of 1 or higher, OR you previously responded well to immunotherapy (with progression-free survival of 6+ months) - Your previous treatment side effects have mostly resolved - Your cancer can be measured on scans - You can provide a tissue sample **You may NOT be eligible if...** - You have not previously received immunotherapy - Your cancer progressed very quickly on prior immunotherapy - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.